Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mepartricin is a semi-synthetic polyene macrolide antibiotic and antifungal agent, structurally a methyl ester of partricin. It is primarily used for the treatment of benign prostatic hyperplasia (BPH), chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS), vaginal candidiasis, and trichomoniasis. Mepartricin acts as an estrogen reabsorption inhibitor in the gut, increasing fecal excretion of estrogens and reducing their levels in the prostate. This mechanism underlies its efficacy in BPH and CPPS by suppressing estrogen-induced prostatic growth and inflammation. Additionally, it exhibits antifungal and antiprotozoal activity through disruption of cell membrane integrity via binding to ergosterol and other sterols[1][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mepartricin.